XBITHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores XBiotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (79): Smaller than most of the companies we track.
Value (14): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on XBIT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Apr 2020 | Piper Sandler | Maintains | Overweight | $28 → $18 |
| 7 Apr 2020 | Piper Sandler | Maintains | Overweight | — |
| 11 Dec 2019 | Piper Sandler | Maintains | Overweight | — |
| 11 Dec 2019 | PiperJaffray | Maintains | Overweight | — |
| 14 June 2019 | Piper Jaffray | Initiates | Overweight | — |
| 14 June 2019 | Piper Sandler | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
XBIT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, XBiotech, Inc. returned −21.7% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 83% of US stocks
Cheaper than 58% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 27% of US stocks
Higher than 20% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
XBiotech, Inc. has a market value of $59.1M and an enterprise value of −$50.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$45.1M.
Free cash flow in the twelve months to 30 June 2026: −$40.8M.
Trailing P/E: −1.3×; forward P/E: 15.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
XBiotech, Inc. employs 87 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own XBiotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
XBiotech announced that its Board elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective Oct. 23, 2026.
Why it matters — XBIT watchers may note the change in the company’s executive leadership structure.
XBiotech reported positive final Phase II efficacy results from the investigator-sponsored TASKIN trial in refractory metastatic colorectal cancer. The study, funded by France’s National Cancer Institute (INCa), met its pre-specified primary efficacy success criterion, with 61.3% 12-month overall survival.
Why it matters — The results provide an update on XBiotech’s clinical research in refractory metastatic colorectal cancer.
As at 31 Oct 2026, XBiotech, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).
No analyst covering XBiotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XBIT are extrapolating price history, which says nothing about the business.
XBiotech, Inc. returned -21.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
XBiotech Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing True Human™ monoclonal antibodies for a range of diseases.
The most recent item we track (GlobeNewsWire, 23 Oct 2026): "XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers". XBiotech announced that its Board elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective Oct. 23, 2026.
XBiotech Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing True Human™ monoclonal antibodies for a range of diseases. Its current programs center on therapeutic antibodies derived from naturally occurring human immunity, with a pipeline that targets inflammatory, infectious, and oncology-related conditions. The company’s product development efforts emphasize antibody-based treatments designed to address diseases driven by immune and inflammatory pathways, including areas such as cancer, rheumatology, and infectious disease. XBiotech Inc. also supports the clinical and preclinical advancement of candidate therapies built around its proprietary antibody platform. Headquartered in Austin, Texas, XBiotech Inc. operates as a research-driven company within the biotechnology sector, where it contributes to the development of next-generation biologic medicines for unmet medical needs.
CEO Dr. Sushma Shivaswamy Ph.D. · 87 employees · United States · https://www.xbiotech.com
